Oncology is moving beyond organ-based categorization—cancer care is now defined by the specific genetic mutations driving the tumor.
As precision medicine takes center stage, three trends are accelerating the Global Solid Tumor Testing Market toward a projected $93.57 Billion by 2034:
Comprehensive Genomic Profiling (CGP): Next-Generation Sequencing (NGS) is replacing single-gene PCR tests. By analyzing hundreds of genes simultaneously from a single biopsy, clinicians can match patients with targeted therapies (like KRAS G12C, EGFR, and PARP inhibitors) without running out of tissue.
Liquid Biopsies & ctDNA Tracking: Blood-based genomic assays are solving biopsy access hurdles, enabling real-time detection of emergent drug-resistance mutations and monitoring minimal residual disease (MRD) months before radiological scans show recurrence.
AI-Driven Variant Interpretation: Automated bioinformatics platforms and digital pathology tools are resolving the interpretation bottleneck, turning complex genomic datasets into actionable treatment roadmaps for molecular tumor boards.
When targeted therapies are paired with the right companion diagnostic, progression-free survival improves while toxic side effects drop.
Explore the full industry analysis and strategic forecast:
https://www.maximizemarketrese....arch.com/market-repo
Request the complete research sample brochure:
https://www.maximizemarketrese....arch.com/request-sam
What is transforming your diagnostic workflow the most: fast-turnaround benchtop NGS or blood-based ctDNA monitoring?
#precisiononcology #solidtumortesting #nextgensequencing #liquidbiopsy #companiondiagnostics #genomics #cancerresearch #moleculardiagnostics #biopharma
喜欢
-
-
-
-
-
-
评论
分享
Oncology is moving beyond organ-based categorization—cancer care is now defined by the specific genetic mutations driving the tumor.
As precision medicine takes center stage, three trends are accelerating the Global Solid Tumor Testing Market toward a projected $93.57 Billion by 2034:
Comprehensive Genomic Profiling (CGP): Next-Generation Sequencing (NGS) is replacing single-gene PCR tests. By analyzing hundreds of genes simultaneously from a single biopsy, clinicians can match patients with targeted therapies (like KRAS G12C, EGFR, and PARP inhibitors) without running out of tissue.
Liquid Biopsies & ctDNA Tracking: Blood-based genomic assays are solving biopsy access hurdles, enabling real-time detection of emergent drug-resistance mutations and monitoring minimal residual disease (MRD) months before radiological scans show recurrence.
AI-Driven Variant Interpretation: Automated bioinformatics platforms and digital pathology tools are resolving the interpretation bottleneck, turning complex genomic datasets into actionable treatment roadmaps for molecular tumor boards.
When targeted therapies are paired with the right companion diagnostic, progression-free survival improves while toxic side effects drop.
Explore the full industry analysis and strategic forecast:
https://www.maximizemarketrese....arch.com/market-repo
Request the complete research sample brochure:
https://www.maximizemarketrese....arch.com/request-sam
What is transforming your diagnostic workflow the most: fast-turnaround benchtop NGS or blood-based ctDNA monitoring?
#precisiononcology #solidtumortesting #nextgensequencing #liquidbiopsy #companiondiagnostics #genomics #cancerresearch #moleculardiagnostics #biopharma
